IP Library › Patent Application 13868753
Patent Application
App. No. 13/868,753

COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/868,753
Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.

Claims (1)

1 . A method of treating a B-cell lymphoma patient comprising administering rituximab to the patient, monitoring for adverse events during therapy and discontinuing therapy if a grade 3 or grade 4 adverse event occurs in the patient, and wherein the adverse event is grade 3 or grade 4 arrhythmia.

Assignments (1)
CHANGE OF NAME Recorded Apr 30, 2015
From: BIOGEN IDEC INC.
To: BIOGEN INC.
Reel/Frame 035552/0202 →